New CEO Ornskov Re-Organizes, Streamlines Shire’s Commercial And R&D Functions
This article was originally published in The Pink Sheet Daily
Top-line revenue was down slightly and Shire reduced its annual sales growth projections a bit too. But Shire’s first quarter earnings call centered on new CEO Flemming Ornskov’s decision to immediately implement a flatter management structure, reorganizing into five commercial business units and consolidating the R&D and business development operations.
You may also be interested in...
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.